Mingxiang Feng

Dr. Mingxiang Feng


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Translational Oncology
Verified
Journal Article
Open access
YZYaoyao Zhuo
Yaoyao Zhuo
MFMingxiang Feng
Mingxiang Feng
SYShuyi Yang
Shuyi Yang
LZLingxiao Zhou
Lingxiao Zhou
DGDi Ge
Di Ge
ZZZhi-yong Zhang
Zhi-yong Zhang
To evaluate the clinical features and radiomics nomograms of tumors and peritumoral regions for the preoperative prediction of the presence of spread through air spaces (STAS) in patients with lung adenocarcinoma. A total of 107 STAS-positive lung adenocarcinomas were selected and matched to 105 STAS-negative lung adenocarcinomas. Thin-slice CT imaging annotation and region of interest (ROI) segmentation were performed with semi-automatic in-house software. Radiomics features were extracted from all nodules and incremental distances of 5, 10, and 15 mm outside the lesion segmentation. A radiomics nomogram was established with multivariable logistic regression based on clinical and radiomics features. The maximum diameter of the solid component and mediastinal lymphadenectasis were selected as independent predictors of STAS. The radiomics nomogram of lung nodules showed especially good prediction in the training set [area under the curve (AUC), 0.98; 95% confidence interval (CI), 0.97–1.00] and test set (AUC, 0.99; 95% CI, 0.97–1.00). The radiomics nomogram of peritumoral regions also showed good prediction, but the fitting degrees of the calibration curves were not good. Our study may provide guidance for surgical methods in patients with lung adenocarcinoma.

15 June 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
XZXi Zhu
Xi Zhu
MDMing Ding
Ming Ding
MYMei-Lan Yu
Mei-Lan Yu
MFMingxiang Feng
Mingxiang Feng
LTLijie Tan
Lijie Tan
FZFu-Kun Zhao
Fu-Kun Zhao
Background: Esophageal squamous cell carcinoma (ESCC) is one of the most common malignancies. Early diagnosis is critical for guiding the therapeutic management of ESCC. It is imperative to find more effective biomarkers of ESCC. Methods: To identify novel biomarkers for esophageal squamous cell carcinoma (ESCC), specimens from 10 patients with ESCC were subjected to a comparative proteomic analysis. The proteomic patterns of ESCC samples and normal esophageal epithelial tissues (NEETs) were compared using two-dimensional gel electrophoresis. And differentially expressed proteins were identified using MALDI-TOF-MS/MS. For further identification of protein in selected spot, western blotting and immunohistochemistry were employed. Results: Twelve proteins were up-regulated and fifteen proteins were down-regulated in the ESCC samples compared with the NEET samples. Up-regulation of galectin-7 was further confirmed by western blotting and immunohistochemistry. Furthermore, immunohistochemical staining of galectin-7 was performed on a tissue microarray containing ESCC samples (n = 50) and NEET samples (n = 10). The expression levels of galectin-7 were markedly higher in the ESCC samples than in the NEET samples (P = 0.012). In addition, tissue microarray analysis also showed that the expression level of galectin-7 was related to the differentiation of ESCC. Conclusions: The present proteomics analysis revealed that galectin-7 was highly expressed in ESCC tissues. The alteration in the expression of galectin-7 was confirmed using a tissue microarray. These findings suggest that galectin-7 could be used as a potential biomarker for ESCC.

24 October 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MZMengnan Zhao
Mengnan Zhao
TLTao Lu
Tao Lu
GBGuoshu Bi
Guoshu Bi
ZHZhengyang Hu
Zhengyang Hu
JLJiaqi Liang
Jiaqi Liang
CZCheng Zhan
Cheng Zhan
Esophageal squamous cell carcinoma (ESCC) is the most common pathological type of esophageal cancer in China, accounting for more than 90 %. Most patients were diagnosed with advanced-stage ESCC, for whom new adjuvant therapy is recommended. Therefore, it is urgent to explore new therapeutic targets for ESCC. Ferroptosis, a newly discovered iron-dependent programmed cell death, has been shown to play an important role in carcinogenesis by many studies. This study explored the effect of Polo like kinase 1 (PLK1) on chemoradiotherapy sensitivity of ESCC through ferroptosis METHODS: In this study, we knocked out the expression of PLK1 (PLK1-KO) in ESCC cell lines (KYSE150 and ECA109) with CRISPR/CAS9. The effects of PLK1-knock out on G6PD, the rate-limiting enzyme of pentose phosphate pathway (PPP), and downstream NADPH and GSH were explored. The lipid peroxidation was observed by flow cytometry, and the changes in mitochondria were observed by transmission electron microscopy. Next, through the CCK-8 assay and clone formation assay, the sensitivity to cobalt 60 rays, paclitaxel, and cisplatin were assessed after PLK1-knock out, and the nude mouse tumorigenesis experiment further verified it. The regulation of transcription factor YY1 on PLK1 was evaluated by dual luciferase reporter assay. The expression and correlation of PLK1 and YY1, and their impact on prognosis were analyzed in more than 300 ESCC cases from the GEO database and our center. Finally, the above results were further proved by single-cell sequencing. After PLK1 knockout, the expression of G6PD dimer and the level of NADPH and GSH in KYSE150 and ECA109 cells significantly decreased. Accordingly, lipid peroxidation increased, mitochondria became smaller, membrane density increased, and ferroptosis was more likely to occur. However, with the stimulation of exogenous GSH (10 mM), there was no significant difference in lipid peroxidation and ferroptosis between the PLK1-KO group and the control group. After ionizing radiation, the PLK1-KO group had higher lipid peroxidation ratio, more cell death, and was more sensitive to radiation, while exogenous GSH (10 mM) could eliminate this difference. Similar results could also be observed when receiving paclitaxel combined with cisplatin and chemoradiotherapy. The expression of PLK1, G6PD dimer, and the level of NADPH and GSH in KYSE150, ECA109, and 293 T cells stably transfected with YY1-shRNAs significantly decreased, and the cells were more sensitive to radiotherapy and chemotherapy. ESCC patients from the GEO database and our center, YY1 and PLK1 expression were significantly positively-correlated, and the survival of patients with high expression of PLK1 was significantly shorter. Further analysis of single-cell sequencing specimens of ESCC in our center confirmed the above results. In ESCC, down-regulation of PLK1 can inhibit PPP, and reduce the level of NADPH and GSH, thereby promoting ferroptosis and improving their sensitivity to radiotherapy and chemotherapy. Transcription factor YY1 has a positive regulatory effect on PLK1, and their expressions were positively correlated. PLK1 may be a target for predicting and enhancing the chemoradiotherapy sensitivity of ESCC.

24 September 2014 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
JLJingpei Li
Jingpei Li
YSYaxing Shen
Yaxing Shen
LTLijie Tan
Lijie Tan
MFMingxiang Feng
Mingxiang Feng
HWHao Wang
Hao Wang
QWQun Wang
Qun Wang

21 September 2010 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
HWHao Wang
Hao Wang
LTLijie Tan
Lijie Tan
MFMingxiang Feng
Mingxiang Feng
YZYi Zhang
Yi Zhang
QWQun Wang
Qun Wang

28 March 2020 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MZMengnan Zhao
Mengnan Zhao
ZCZhencong Chen
Zhencong Chen
YZYuansheng Zheng
Yuansheng Zheng
JLJiaqi Liang
Jiaqi Liang
ZHZhengyang Hu
Zhengyang Hu
QWQun Wang
Qun Wang